Zogenix sends last patient into second Phase 3 trial for its supporting treatment for Dravet syndrome young patients
Zogenix, a NASDAQ-listed pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, has randomized the last…